<DOC>
	<DOCNO>NCT00959699</DOCNO>
	<brief_summary>The primary objective trial compare efficacy boceprevir ( SCH 503034 ) 800 mg three time day ( TID ) orally ( PO ) combination peginterferon alfa-2b ( PegIFN-2b ) 1.5 µg/kg weekly ( QW ) subcutaneously ( SC ) plus weight-based dosing ( WBD ) ribavirin ( RBV ) ( 600 mg/day 1400 mg/day ) PO therapy PegIFN-2b + RBV alone adult participant coinfected human immunodeficiency virus ( HIV ) previously untreated chronic hepatitis C virus ( HCV ) genotype 1 . Boceprevir potent , orally administer , novel serine protease inhibitor , specifically design inhibit HCV nonstructural protein 3 ( NS3 ) protease , thereby , inhibit viral replication HCV-infected host cell . The mechanism inhibition represent new mechanism action compare interferon alfa ribavirin . Based previous experience PegIFN-2b RBV combination boceprevir HCV-monoinfected population , combination treatment expect provide significant benefit HIV/HCV coinfected population . Given high unmet medical need participant benefit addition boceprevir PegIFN-2b/RBV , important demonstrate safety efficacy boceprevir combination PegIFN-2b/RBV participant coinfected HIV/HCV . This randomized , multi-center trial , double-blinded boceprevir placebo combination open-label PegIFN-2b/RBV participant coinfected HIV previously untreated chronic HCV ( genotype 1 ) , conduct conformance Good Clinical Practice ( GCP ) . This trial consist two arm , one control arm ( Arm 1 ) one experimental arm ( Arm 2 ) . Participants control arm ( Arm 1 ) may receive boceprevir/PegIFN-2b/RBV via crossover arm .</brief_summary>
	<brief_title>A Phase 2b , Safety Efficacy Study Boceprevir Patients Coinfected With HIV Hepatitis C ( P05411 AM4 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>&gt; =18 &lt; =65 year age Body weight &gt; =40 &lt; =125 kg Documented history HIV infection great 6 month prior Day 1 On optimized antiretroviral treatment regimen ( OTR ) stable HIV disease CD4 &gt; =200 cells/µL HIV1 RNA viral load &lt; 50 copies/mL Documented chronic hepatitis C ( CHC ) genotype 1 infection ( great 6 month prior Day 1 ) Use acceptable method contraception 2 week prior Day 1 least 6 month longer treatment Liver biopsy histology consistent CHC etiology Participants receive prior treatment hepatitis C herbal remedy except know hepatotoxicity Coinfected hepatitis B virus ( Hepatitis B surface antigen ( HBsAg ) positive ) and/or demonstrate sign symptom consistent concomitant infection Evidence decompensated liver disease Participants change antiretroviral regimen within last 3 month prior Day 1 first initiated antiretroviral therapy within last 6 month prior Day 1 Use certain HIV medication allow . Medications review Investigator History clinically significant opportunistic infection ( except oral thrush ) within last year prior Day 1 Current evidence substance abuse within 3 year Screening Visit History clinical diagnosis within past 6 month substance abuse prior Day 1 Participants receive opiate agonist substitution therapy enrol opiate substitution maintenance program History marijuana use deem excessive Investigator Infected HIV2 Use HIV protease inhibitor without coadministration ritonavir within one month Day 1 throughout period trial Participants receive follow medication ( ) within 2 week prior Day 1 visit : alfuzosin , antiarrhythmic ( amiodarone , bepridil , flecainide , propafenone , quinidine ) , ergot derivative , cisapride , lovastatin , simvastatin , pimozide , triazolam , orally administer midazolam . Key Laboratory Hematologic , biochemical , serologic criterion ( growth factor may use achieve trial entry requirement ) : Hemoglobin &lt; 11 g/dL female &lt; 12 g/dL male Neutrophils &lt; 1500/mm^3 ( blacks/AfricanAmericans : &lt; 1200/mm^3 ) Platelets &lt; 100,000/mm^3 Direct bilirubin &gt; 1.5 x ULN ( upper limit normal ) laboratory reference range . Total bilirubin &gt; 1.6 mg/dL unless history Gilbert 's disease antiretroviral regimen contain atazanavir . If Gilbert 's disease propose etiology , must document participant 's chart Alpha fetoprotein ( AFP ) : AFP &gt; 100 ng/mL OR AFP 50 100 ng/mL ( require liver ultrasound participant finding suspicious hepatocellular carcinoma exclude )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>coinfection</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>HIV</keyword>
</DOC>